References
- Shaw RW. A risk benefit assessment of drugs used in the treatment of endometriosis. Drug Safety 1994; 11: 104–13
- Bergqvist A, Bergh T, Hogström L, et al. Effects of triptorelin versus placebo on the symptoms of endometriosis. Fertil Steril 1998; 69: 702–8
- Waller KG, Shaw RW. Gonadotropin-releasing hormone analogues for the treatment of endometriosis: long-term follow-up. Fertil Steril 1993; 59: 511–5
- Bergqvist A. Hormonal regulation of endometriosis and the rationales and effects of gonadotrophin-releasing hormone agonist treatment: a review. Hum Reprod 1995; 10: 446–52
- The American Fertility Society. Revised American Fertility Society Classification of endometriosis. Fertil Steril 1985; 43: 351–2
- Döberl A, Bergqvist A, Jeppsson S, et al. Regression of endometriosis following shorter treatment with or lower dose of danazol. Acta Obstet Gynecol Scand (suppl.) 1984; 123: 51–8
- Brosens I, Donnez J, Benagiano G. Improving the classification of endometriosis. Hum Reprod 1993; 8: 1792–5
- American Society for Reproductive Medicine. Revised American Society for Reproductive Medicine classification of endometriosis: 1996. Fertil Steril 1997; 67: 817–21
- Chrisp P, Goa KL. Goserelin. A review of its pharmacodynamic and pharmacokinetic properties, and clinical use in sex hormone-related conditions. Drugs 1991; 41: 254–88
- Barbieri RL. Hormone treatment of endometriosis: the estrogens threshold hypothesis. Am J Obstet Gynecol 1992; 166: 740–5
- Agarwal SK, Hamrang C, Henzl MR, , the Nafarelin Study Group, et al. Nafarelin vs. leuprolide acetate depot for endometriosis. Changes in bone mineral density and vasomotor symptoms. J Reprod Med 1997; 42: 1–11
- Wiegerinck MA, Van Dop PA, Brosens IA. The staging of peritoneal endometriosis by the type of active lesion in addition to the revised American Fertility Society classification. Fertil Steril 1993; 60: 461–4
- Bergqvist A, Fernö M. Estrogens and progesterone receptors in endometriotic tissue and endometrium: comparison according to localisation and recurrence. Fertil Steril 1993; 60: 63–8
- Uemura T, Mohri J, Osada H, et al. Effect of gonadotropin-releasing hormone agonist on the bone mineral density of patients with endometriosis. Fertil Steril 1994; 62: 246–50
- Paoletti AM, Serra GG, Cagnacci A, et al. Spontaneous reversibility of bone loss induced by gonadotropin-releasing hormone analog treatment. Fertil Steril 1996; 65: 707–10
- Rock JA, Truglia JA, Caplan RJ, et al. Zoladex (goserelin acetate implant) in the treatment of endometriosis: a randomised comparison with danazol. Obstet Gynecol 1993; 82: 198–205
- Hayslip CC, Klein TA, Wray HL, et al. The effect of lactation on bone mineral content in healthy postpartum women. Obstet Gynecol 1989; 73: 588–92
- Adashi EY. Long-term gonadotrophin-releasing hormone agonist therapy: the evolving issue of steroidal ‘add-back’ paradigms. Human Reprod Update 1994; 9: 1380–97
- Regidor PA, Regidor M, Kato K, et al. Long-term follow-up on the treatment of endometriosis with the GnRH-agonist buserelin acetate. Long-term follow-up data (up to 98 months) of 42 patients with endometriosis who were treated with GnRH-agonist buserelin acetate (Suprecur) were evaluated in respect of recurrence of pain symptoms and pregnancy outcome. Eur J Obstet Gynecol Reprod Biol 1997; 73: 153–60